Imperative ethical behaviours in making systems development and deployment compliant with health & safety and well-being

Literature on systems development has been progressively identifying the importance of social aspects in systems development, to the extent that this process has been considered a socio-technical system. More often than not there is a failure of participants in the recognition, and fulfilment, of ethical duties concerning the concepts of health and safety and wellbeing. The purpose of normative ethics is to scrutinise moral standards for the rightness and wrongness of actions, the ultimate goal being the identification of the true human good. A rational appeal can be made to normative defensible ethical rules in order to arrive at a judicious, morally justifiable judgement. In this paper our first step is to report on the findings of a literature review, which presents the current health and safety issues concerning usage of computers in organisations and the workplace. Secondly, we identify and list some basic generic Deontological and Teleological moral principles and theories that can serve as normative guidelines for addressing the issues pinpointed in the initial step. Thirdly, we prescribe a set of moral rights and duties that must be exercised and fulfilled by protagonists in systems development and software engineering in order for them to exhibit moral behaviour. Each of these suggested actions are substantiated via an appeal to one, or a number of the normative guidelines, identified in the second step. By identifying, and recommending a set of defensible moral obligations that must be fulfilled in the development and deployment of systems, protagonists such as: project managers, software engineering teams, systems analysts, clients, etc. can fulfil their ethical duties, thus increasing the likelihood a deployed system that is compliant with principles of health and safety and wellbeing of its users. Ultimately systems development and deployment must be underpinned with ethical consideration

Should Research Ethics Encourage the Production of Cost-Effective Interventions?

This project considers whether and how research ethics can contribute to the provision of cost-effective medical interventions. Clinical research ethics represents an underexplored context for the promotion of cost-effectiveness. In particular, although scholars have recently argued that research on less-expensive, less-effective interventions can be ethical, there has been little or no discussion of whether ethical considerations justify curtailing research on more expensive, more effective interventions. Yet considering cost-effectiveness at the research stage can help ensure that scarce resources such as tissue samples or limited subject popula- tions are employed where they do the most good; can support parallel efforts by providers and insurers to promote cost-effectiveness; and can ensure that research has social value and benefits subjects. I discuss and rebut potential objections to the consideration of cost-effectiveness in research, including the difficulty of predicting effectiveness and cost at the research stage, concerns about limitations in cost-effectiveness analysis, and worries about overly limiting researchers’ freedom. I then consider the advantages and disadvantages of having certain participants in the research enterprise, including IRBs, advisory committees, sponsors, investigators, and subjects, consider cost-effectiveness. The project concludes by qualifiedly endorsing the consideration of cost-effectiveness at the research stage. While incorporating cost-effectiveness considerations into the ethical evaluation of human subjects research will not on its own ensure that the health care system realizes cost-effectiveness goals, doing so nonetheless represents an important part of a broader effort to control rising medical costs

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly

<div><h3>Background</h3><p>The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (GH) levels in patients with acromegaly and may also induce pituitary tumor shrinkage.</p> <h3>Objective</h3><p>We performed a meta-analysis to accurately assess the effect of octreotide on pituitary tumor shrinkage.</p> <h3>Data Sources</h3><p>A computerized Medline and Embase search was undertaken to identify potentially eligible studies.</p> <h3>Study Eligibility Criteria</h3><p>Eligibility criteria included treatment with octreotide, availability of numerical metrics on tumor shrinkage and clear definition of a clinically relevant reduction in tumor size. Primary endpoints included the proportion of patients with tumor shrinkage and mean percentage reduction in tumor volume.</p> <h3>Data Extraction and Analysis</h3><p>The electronic search identified 2202 articles. Of these, 41 studies fulfilling the eligibility criteria were selected for data extraction and analysis. In total, 1685 patients were included, ranging from 6 to 189 patients per trial. For the analysis of the effect of octreotide on pituitary tumor shrinkage a random effect model was used to account for differences in both effect size and sampling error.</p> <h3>Results</h3><p>Octreotide was shown to induce tumor shrinkage in 53.0% [95% CI: 45.0%–61.0%] of treated patients. In patients treated with the LAR formulation of octreotide, this increased to 66.0%, [95% CI: 57.0%–74.0%). In the nine studies in which tumor shrinkage was quantified, the overall weighted mean percentage reduction in tumor size was 37.4% [95% CI: 22.4%–52.4%], rising to 50.6% [95% CI: 42.7%–58.4%] with octreotide LAR.</p> <h3>Limitations</h3><p>Most trials examined were open-label and had no control group.</p> <h3>Conclusions</h3><p>Octreotide LAR induces clinically relevant tumor shrinkage in more than half of patients with acromegaly.</p> </div

Genetic Testing and Human Genetic Databases

Genetic databases would not exist without the input from donors. Their samples and their associated information are the foundation of their existence. Genetic databases contain very personal, sensitive information and, if misused, could lead to any number of potential harms for the donor. Consequently, the operation and use of genetic databases should meet the highest ethical standards backed up by effective regulations and legislation. The aim of this chapter is to first describe genetic databases and their function before turning to two of the most controversial ethical issues that surround genetic databases, namely privacy and informed consent and describe how the Australian Government has so far responded to these challenges. It will close by turning to an explicit example, that is, the National Criminal Investigation DNA Database (NCIDD), which is one of a web of databases overseen by the CrimTrac agency of Australia

Nanoethics: Old Wine, New Bottles?

Nanoethics, Nanoproducts, Nanomedicine, Precaution, Product liability,